The MGH/NERPRC Center for the Study of Inflammatory Bowel Disease is a multidisciplinary program to define fundamental mechanisms underlying Crohn's disease and ulcerative colitis. While a number of provocative and useful observations offer some insights into inflammatory bowel disease (IBD), progress in understanding these common disorders has been slow and new initiatives are needed. Clinical experience and past research efforts serve to underscore the apparent intrinsic complexity of these disorders. Most importantly, progress in IBD research has been limited by both the need for advances in a number of relevant basic fields of gastrointestinal science and sufficient interest in the scientific community to explore the relevance of findings in these areas to IBD. This Center, encompassing workers at the Massachusetts General Hospital and the New England Regional Primate Research Center, includes both scientists pursuing a broad spectrum of areas of basic science relevant to IBD and investigators with established commitment to the study of IBD to promote progress in the understanding of IBD. It is anticipated that this center for research and investigator development will serve as a national resource for the advance in our understanding of IBD. The broad goal of advancing our knowledge of IBD will be promoted through the several biomedical core resources of this center. These cores which will function to provide both service as well as training/consultation, include a Molecular Biology Core, a Morphology core and an Immunology/Inflammatory Core. In addition, a Primate MOdel Core and a Clinical/Tissue Core will provide the needs of the research center with the active program of patient care and clinical investigation at the MGH and to establish a reference source of well characterized tissue and serum that can serve as a center and national resource. The Primate Model Core will also serve as a unique national resource in the study of the Cotton-top tamarin as a model of chronic colitis by making it available not only for the gastrointestinal research community of this center but also nationally. In addition to advancing the understanding of IBD per se, the goals of this center include 1) the recruitment of established investigators to the study of inflammatory bowel disease and 2) the development of a resource for the training of new investigators committed to pursuing IBD research. A pilot feasibility program in support of these goals will place special relevance on proposals to explore the extension of work emerging from the laboratories of allied basic scientists in a manner relevant to IBD as well as innovative projects of other members who will benefit from the core resources. It is hoped that this mechanism will contribute to the overall goal of increasing the complement of investigators focused on the pathogenesis, diagnosis and treatment of IBD.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK043351-05
Application #
2142938
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Project Start
1991-02-05
Project End
1995-12-31
Budget Start
1995-03-01
Budget End
1995-12-31
Support Year
5
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Islam, Kamrul; Hossain, Motaher; Kelly, Meagan et al. (2018) Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers. PLoS Negl Trop Dis 12:e0006376
Lidofsky, Anna; Holmes, Jacinta A; Feeney, Eoin R et al. (2018) Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection. J Infect Dis 218:1394-1403
Kruger, Annie J; Fuchs, Bryan C; Masia, Ricard et al. (2018) Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet-induced mouse model of nonalcoholic steatohepatitis. Hepatol Commun 2:529-545
Moran, Christopher J; Huang, Hailiang; Rivas, Manuel et al. (2018) Genetic variants in cellular transport do not affect mesalamine response in ulcerative colitis. PLoS One 13:e0192806
Dougan, Michael; Ingram, Jessica R; Jeong, Hee-Jin et al. (2018) Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1-Specific VHHs. Cancer Immunol Res 6:389-401
Nalagatla, Niharika; Falloon, Katherine; Tran, Gloria et al. (2018) Effect of Accelerated Infliximab Induction on Short- and Long-Term Outcomes of Acute Severe Ulcerative Colitis: A Retrospective Multicenter Study and Meta-Analysis. Clin Gastroenterol Hepatol :
Ma, Siyuan; Ogino, Shuji; Parsana, Princy et al. (2018) Continuity of transcriptomes among colorectal cancer subtypes based on meta-analysis. Genome Biol 19:142
Midani, Firas S; Weil, Ana A; Chowdhury, Fahima et al. (2018) Human Gut Microbiota Predicts Susceptibility to Vibrio cholerae Infection. J Infect Dis 218:645-653
Bourgeois, Soline; Bounoure, Lisa; Mouro-Chanteloup, Isabelle et al. (2018) The ammonia transporter RhCG modulates urinary acidification by interacting with the vacuolar proton-ATPases in renal intercalated cells. Kidney Int 93:390-402
Luther, Jay; Gala, Manish K; Borren, Nynke et al. (2018) Hepatic connexin 32 associates with nonalcoholic fatty liver disease severity. Hepatol Commun 2:786-797

Showing the most recent 10 out of 1166 publications